Please provide your email address to receive an email when new articles are posted on . Over the past several months, two new agents have become available to aid clinicians in preventing infections ...

Opportunities in the varizig market stem from rising VZV infections and healthcare spending, emphasizing passive immunization and high-risk patient protection. Growth is fueled by advancements in ...

VARIZIG Lyophilized (varicella zoster immune globulin [human]) The FDA has approved Varizig (varicella zoster immune globulin [human]; Cangene) for reducing the severity of chicken pox (varicella ...

ROSWELL, Ga., Jan. 14, 2019 /PRNewswire-PRWeb/ -- The Centers for Disease Control (CDC) has updated information related to the use and availability of VARIZIG® (Varicella Zoster Immune Globulin [Human ...

REHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for ...

Varicella zoster immune globulin (VZIG) has been the mainstay of therapy for postexposure prophylaxis of varicella for patients at high risk for severe disease and complications. However, the U.S.

(RTTNews) - Kamada Ltd. (KMDA), a biopharmaceutical company specializing in rare and serious conditions, announced on Monday that it has been awarded a three-year contract with an international ...

(MENAFN- GlobeNewsWire - Nasdaq) Opportunities in the varizig market stem from rising VZV infections and healthcare spending, emphasizing passive immunization and high-risk patient protection. Growth ...